Short Communication

Binding of Lopinavir to Human $\alpha_1$-Acid Glycoprotein and Serum Albumin

Received January 13, 2009; accepted May 12, 2009

ABSTRACT:

HIV protease inhibitors are an important component of highly active antiretroviral therapy used to treat pregnant women infected with HIV. They have a low placental transfer and are highly plasma protein bound. This study was carried out to determine the unbound fraction of lopinavir in cord blood, and to characterize the binding of lopinavir to $\alpha_1$-acid glycoprotein (AAG) and human serum albumin (HSA), and displacement by ritonavir. Serum was obtained from cord blood from placentas obtained after cesarean section of healthy, non-HIV-infected women ($n = 4$). The unbound fraction of lopinavir in serum obtained from this cord blood was 0.022 ± 0.011%. The unbound fraction of lopinavir in separately obtained maternal serum samples ($n = 4$) was 0.89 ± 0.12%, which was not significantly different from that observed with cord serum samples. Varying concentrations of lopinavir, AAG, and HSA in buffer solutions were then used to characterize the lopinavir binding. The data were fit to obtain the number of binding sites ($N$) and equilibrium dissociation constant ($K_d$). Binding of lopinavir to AAG (7–23 $\mu$M) was saturable with $K_d$ of 5.0 ± 1.1 $\mu$M and $N$ of 1.2 ± 0.2. At low HSA concentrations (15–152 $\mu$M), lopinavir binding $K_d$ was 24.3 ± 8.7 $\mu$M and $N$ was 1.1 ± 0.4; however, at 758 $\mu$M, lopinavir binding was essentially unsaturable. Lopinavir binding to AAG and HSA was not sensitive to ritonavir, and, thus, efforts to enhance fetal exposure to lopinavir should be focused on other issues such as efflux transporters.

Highly active antiretroviral therapy is used to treat patients infected with HIV, involving the administration of multiple antiretroviral drugs acting at different steps of the HIV life cycle. In treating pregnant patients infected with HIV, the aim of therapy is not only the treatment of the mother but also to prevent the transmission of the virus to the fetus. Among the antiretroviral drugs used, there are differences in the extent of transfer of these drugs across the placenta; HIV protease inhibitors are particularly poorly transferred.

The placenta separates maternal and fetal blood circulations, wherein the concentrations of drug-binding proteins are high in both circulations. However, they are unequal and dynamic over time. This protein concentration gradient favors partitioning of total drug on the maternal side for highly plasma protein-bound drugs like HIV protease inhibitors (most >98%). It has been shown that concentrations of plasma proteins such as $\alpha_1$-acid glycoprotein (AAG) and albumin change during the gestation period. Between 12 and 41 weeks of gestation, maternal serum albumin concentration ranges from 311 to 583 $\mu$M, whereas fetal serum albumin ranges from 114 to 603 $\mu$M (Krauer et al., 1984) and as high as 659 $\mu$M (Nation, 1981). Maternal serum AAG concentration, on the other hand, ranges from 7 to 24 $\mu$M (Krauer et al., 1984) and as high as 46 $\mu$M in the presence of acute or chronic inflammation (Chu et al., 1981). Fetal serum AAG concentrations range from ≤0.2 to 9 $\mu$M (Krauer et al., 1984). Similar plasma/serum protein concentration ranges have been observed in other studies as well (Laurell, 1968; Ganrot, 1972; Chu et al., 1981; Nation, 1981; Wood and Wood, 1981; Raynes, 1982; Denson et al., 1984; Krauer et al., 1984). Thus, the binding of highly plasma protein-bound drugs, such as HIV protease inhibitors, changes during gestation.

In addition, because of concentration differences of proteins in the maternal and fetal circulations, it is important to determine the unbound fraction of the protease inhibitors, not only in the maternal blood but also in the fetal/cord blood. Sudhakaran et al. (2007) observed a higher unbound fraction of indinavir and saquinavir in cord plasma compared with maternal plasma and suggested that this binding differential was due to the transplacental AAG concentration gradient. Therefore, the protein concentration gradient that exists in the maternal and fetal circulations during pregnancy may unfavorably affect partitioning of the drug into the fetal compartment.

Lopinavir was chosen as the drug to study because its combination with ritonavir is currently the drug combination of choice to treat HIV-infected pregnant women. Thus, the purpose of this study was to determine the unbound fraction of lopinavir in cord blood and to characterize the binding kinetics of lopinavir to human AAG and human serum albumin (HSA). Therefore, in this study, we determined the unbound fraction of lopinavir in serum obtained from cord blood. We also studied the binding of lopinavir to AAG and HSA. The AAG and HSA concentrations we used covered the concentration ranges occurring during gestation as discussed above. Because ritonavir is used clinically with lopinavir to enhance lopinavir exposure, we also determined the effect of ritonavir on lopinavir binding to these plasma proteins

**ABBREVIATIONS:** AAG, $\alpha_1$-acid glycoprotein; HSA, human serum albumin; PBS, phosphate-buffered saline.
proteins in a physiologic buffer. The role of ritonavir as a displacer of lopinavir protein binding for potential utility in increasing the maternal-to-fetal placental transfer was also investigated.

Materials and Methods

AAG was obtained from Thermo Fisher Scientific (Waltham, MA) and from Sigma-Aldrich (St. Louis, MO). HSA was obtained from Thermo Fisher Scientific. Lopinavir and [³H]lopinavir (specific activity of 100–139 mCi/ mmol) were obtained from AK Scientific (Mountain View, CA) and Moravek Biochemicals (Brea, CA), respectively. Ritonavir was obtained from Sigma-Aldrich and Bosche Scientific (New Brunswick, NJ).

Placentas were obtained from four women (between the ages of 18–45 years, gestational length ≥36 weeks) from cesarean section deliveries following normal pregnancies at the VCU Medical Center Hospital. The study was approved by the VCU Institutional Review Board (protocol no. 4212), and informed consent was obtained from patients prior to delivery. Patients with hypertension, diabetes, preeclampsia, HIV infection or febrile illness, and patients with a history of smoking, alcohol, or drug abuse were excluded. Maternal blood samples were not available in this study. Cord blood was obtained from placenta within 30 min of birth, allowed to clot on ice, and centrifuged to obtain serum. Maternal serum samples were purchased from BioChemed Services (Winchester, VA). These samples were obtained from nonsmoking pregnant patients aged 19 to 34 years between 17 and 27 weeks gestation.

Rapid equilibrium dialysis (Thermo Scientific Pierce, Rockford, IL), with a molecular weight cutoff of 8,000 Da, was used to determine the protein binding of lopinavir in maternal serum and in serum obtained from cord blood. These protein-binding experiments with serum samples were followed by experiments with varying concentrations of lopinavir, AAG, and HSA. The protein solutions were prepared in phosphate-buffered saline (PBS), pH 7.4. The final concentrations of lopinavir were 0.1, 0.32, 1, 3, 10, 30, and 100 µM. Protein binding of lopinavir was determined in the presence of AAG (7 and 23 µM) and HSA (15, 152, and 758 µM). The protein solution (500 µl) containing the drug was added to the sample (inner) chamber, and 750 µl of PBS was added in the buffer (outer) chamber. Nonspecific binding was determined by adding PBS in both the compartments with the solution in the sample chamber containing [³H]lopinavir alone. The Teflon base plate containing the inserts was covered and incubated at 37°C on an orbital shaker at 100 rpm. Samples (50 µl for serum experiments and 100 µl for the other experiments) were removed from each side at various times up to 16 h, and [³H]lopinavir in sample and buffer compartments was detected by liquid scintillation counting on a Packard TR2800 scintillation analyzer (Perkin-Elmer, Downers Grove, IL). Fraction unbound was determined by taking the ratio of mass of radioactivity observed in the buffer chamber to that in the sample chamber. All determinations were made in triplicates.

The equation for drug binding to a protein is given by:

\[
\frac{B}{P_f} = \frac{N[\text{Lopinavir}]}{K_D + [\text{Lopinavir}]}
\]

where \(B\) is the bound drug concentration, \(P_f\) is the total protein concentration, \(N\) is the number of binding sites per protein molecule, \(K_D\) is the equilibrium dissociation constant, and \([\text{Lopinavir}]\) is the free drug concentration. Binding parameters \(N\) and \(K_D\) were determined by nonlinear least-squares regression using eq. 1 (GraphPad Prism version 5; GraphPad Software Inc., San Diego, CA).

These studies were followed by selecting a physiologic maternal concentration of AAG (9 µM) or HSA (530 µM) and carrying out the determination of lopinavir protein binding at lopinavir concentrations ranging from 0.1 to 30 µM in the presence of different concentrations (0, 1, 10, 25, and 50 µM) of ritonavir. Lopinavir protein binding to HSA (530 µM) was also determined in the presence of a higher ritonavir concentration of 100 µM. Data from HSA and AAG experiments were analyzed by two-way analysis of variance with Bonferroni’s post-test; significance was assessed at \(p < 0.05\). Binding of lopinavir in cord and maternal serum was compared using an unpaired \(t\) test with Welch’s correction (GraphPad Prism version 5).

Results and Discussion

Protein-binding equilibrium was achieved within 16 h, and nonspecific binding was negligible. Fraction unbound for lopinavir in serum obtained from cord serum obtained from term placenta of healthy patients was 0.022 ± 0.011% (mean ± S.D., \(n = 4\)). Our results are similar to the data of Else et al. (2007) (0.017 ± 0.010%) who reported the protein binding of lopinavir in plasma from cord blood of HIV-positive pregnant women at term and on lopinavir/ritonavir therapy. Fraction unbound for lopinavir in maternal serum samples was 0.0089 ± 0.0012% (mean ± S.D., \(n = 4\)), which was not significantly different from that observed with cord serum obtained from term placenta (\(p = 0.099\)). It is noteworthy that the variances were significantly different (\(p < 0.01\)), which may imply more variability in unbound fraction of lopinavir in fetal blood.

Lopinavir binding to 7 and 23 µM AAG at varying drug concentrations (0.1–30 µM) to 7 µM AAG (●) and at 0.1 to 100 µM to 23 µM AAG (□). B, bound lopinavir concentrations normalized for AAG concentration as a function of unbound lopinavir concentrations. AAG: 7 µM (●); 23 µM (□). LOP, lopinavir.

![Figure 1](https://example.com/image1.png)

FIG. 1. Lopinavir binding to AAG. A, lopinavir binding at varying drug concentrations (0.1–30 µM) to 7 µM AAG (●) and at 0.1 to 100 µM to 23 µM AAG (□). B, bound lopinavir concentrations normalized for AAG concentration as a function of unbound lopinavir concentrations. AAG: 7 µM (●); 23 µM (□). LOP, lopinavir.
of a low HSA concentration (15 μM) due to the low solubility of lopinavir. At 758 μM HSA, fraction bound of lopinavir (0.96 ± 0.02) was independent of lopinavir concentration (0.1–100 μM). The data obtained for binding of lopinavir to varying HSA concentrations were also simultaneously fit to eq. 1 with weighting (1/y²). Figure 2B shows saturation binding curve of lopinavir at 15, 152, and 758 μM HSA concentrations. Kd was estimated to be 24.3 ± 8.7 μM and n was 1.1 ± 0.4. However, at a physiologic concentration of 758 μM HSA, lopinavir binding was essentially nonsaturable.

The Kd values obtained in the case of experiments with AAG and HSA can be compared with the therapeutic concentrations of lopinavir to determine whether the binding is saturable or nonsaturable. Lopinavir Cmax following administration of 400 mg of lopinavir with 100 mg of ritonavir to healthy male volunteers is 13.5 μM (http://www.fda.gov/cder/foi/nda/2000/21-226_Kaletra_biopharmr_P1.pdf). However, the estimated unbound lopinavir concentration would be approximately 0.2 μM. In our study, Kd for lopinavir binding to AAG and HSA of 5.0 ± 1.1 and 24.3 ± 8.7 μM, respectively, were much higher than the estimated unbound lopinavir concentration. Thus, lopinavir binding to both AAG and HSA would be nonsaturable at therapeutic concentrations.

Our data indicate that binding to HSA and AAG can account for the total protein binding of lopinavir by multiplying the expected unbound fractions of lopinavir at those protein concentrations. For the AAG and HSA concentration ranges previously discussed, the predicted lopinavir protein binding would vary between 0.96 to 0.99% in the maternal serum and 0.86 to 0.98% in the fetal serum during the course of pregnancy, because protein concentrations in maternal and fetal serum change between 12 and 41 weeks gestation. The range of these predictions includes our observed unbound fractions in both fetal and maternal serum. The trend in the present results toward a higher unbound fraction for lopinavir in cord serum is consistent with the higher unbound fraction in cord blood reported for indinavir and saquinavir (Sudhakaran et al., 2007).

This study shows that protein binding of lopinavir is characterized by saturable binding to AAG and nonsaturable binding to albumin at physiologic protein concentrations. Although HSA binds lopinavir with a somewhat lower affinity and both proteins appear to bind lopinavir at a single site, the physiologic concentration of HSA is much greater resulting in a much higher binding capacity. As a result, HSA would contribute more to the high degree of total plasma protein binding of lopinavir.

The concentration of serum proteins, the number of binding sites, and the apparent Kd determine the extent to which drugs such as lopinavir are bound to proteins. It is anticipated that in the absence of active transport processes, equilibrium would occur for unbound concentrations in fetal and maternal blood for drugs with a long half-life. Thus, changes in fraction unbound (due to alterations in binding kinetics) in either circulation would change the fetal to maternal serum total drug concentration ratios, whereas the unbound concentration ratios would presumably remain constant.

Effect of Ritonavir on Lopinavir Binding to AAG and HSA. Figure 3A shows the binding of lopinavir to 9 μM AAG at various-lopinavir concentrations (0.1–30 μM) in the presence of ritonavir (0, 1, 10, 25, or 50 μM). Lopinavir binding to AAG was significantly displaced by ritonavir only at 50 μM but not lower concentrations; it was not possible to obtain a reliable estimate of Kd. Figure 3B shows lopinavir binding to 530 μM HSA at various lopinavir concentrations (0.1–30 μM) in the presence of ritonavir (0, 1, 10, or 100 μM).
Ritonavir (1 and 10 µM) had no apparent effect on unbound fraction of lopinavir in the presence of 530 µM HSA. In the presence of 100 µM ritonavir (but not lower concentrations), lopinavir binding to HSA was significantly altered.

In addition, ritonavir that is coadministered with lopinavir to pregnant women infected with HIV may not act to displace lopinavir from binding to AAG or HSA at its therapeutically relevant concentrations ($C_{\text{max}} = 0.83$ µM, $C_{\text{trough}} = 0.30$ µM) (Murphy et al., 2001). Therefore, efforts to enhance fetal exposure to lopinavir should probably focus on other mechanisms such as ATP-binding cassette transporters present on the apical (maternal-facing) syncytiotrophoblast. Moreover, mechanistic studies of transplacental transfer of drugs should consider unbound fetal to maternal concentration ratios, especially for highly protein bound drugs.

Virginia Commonwealth University, Medical College of Virginia Campus, Department of Pharmaceutics, Richmond, Virginia

References


Address correspondence to: Dr. Phillip M. Gerk, Department of Pharmaceutics, Virginia Commonwealth University, MCV Campus, 410 N. 12th Street, PO Box 980533, Richmond, VA. E-mail: pmgerk@vcu.edu